{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["158(10)"],"submitter":["Yiu ZZN"],"pubmed_abstract":["<h4>Importance</h4>Drug survival of biologic therapies for psoriasis is a proxy for longer-term treatment effectiveness and safety. Patient factors that are associated with the survival of each biologic differently (effect modifiers) may inform the decision to choose between biologics.<h4>Objective</h4>To assess the drug survival associated with the effectiveness and safety of commonly used biologics for psoriasis in the UK and Ireland and identify effect modifiers for these biologics and their survival.<h4>Design, setting, and participants</h4>We conducted a prospective cohort study of patients with psoriasis using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) between November 2007 and August 2021.<h4>Exposures</h4>Adalimumab, ustekin"],"journal":["JAMA dermatology"],"pagination":["1131-1141"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9260644"],"repository":["biostudies-literature"],"pubmed_title":["Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis."],"pmcid":["PMC9260644"],"pubmed_authors":["Mackenzie T","McElhone K","BADBIR Study Group","Ahmed S","Lunt M","Richards J","Smith CH","Barker J","Hampton P","Yiu ZZN","Browne F","Burden D","Lawson L","McPherson T","Bewley A","Laws P","Murphy R","Owen C","Walton S","Reynolds NJ","Turnbull Jones L","Becher G","Evans I","Alabas O","Griffiths CEM","Symons C","Pearson E","Kirby B","Kleyn E","Warren RB","Morrison S"],"additional_accession":[]},"is_claimable":false,"name":"Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.","description":"<h4>Importance</h4>Drug survival of biologic therapies for psoriasis is a proxy for longer-term treatment effectiveness and safety. Patient factors that are associated with the survival of each biologic differently (effect modifiers) may inform the decision to choose between biologics.<h4>Objective</h4>To assess the drug survival associated with the effectiveness and safety of commonly used biologics for psoriasis in the UK and Ireland and identify effect modifiers for these biologics and their survival.<h4>Design, setting, and participants</h4>We conducted a prospective cohort study of patients with psoriasis using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) between November 2007 and August 2021.<h4>Exposures</h4>Adalimumab, ustekin","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-19T11:51:32.654Z","creation":"2025-04-19T11:51:32.654Z"},"accession":"S-EPMC9260644","cross_references":{"pubmed":["35791876"],"doi":["10.1001/jamadermatol.2022.2909"]}}